How Often Should Adults Have a Skin Cancer Check?
Most countries don't recommend routine skin cancer screening for the general population — despite it being the most common cancer in many of them. Here's what guidelines say, why Australia has no programme despite the world's highest rates, and who genuinely needs regular checks.
Key Takeaway
Most countries — including Australia, which has the world’s highest melanoma rates — do not recommend routine skin cancer screening for the general population, because population-wide screening hasn’t been shown to reduce mortality. Germany is the notable exception, offering statutory full-body checks every two years from age 35. For higher-risk adults, annual or twice-yearly skin checks by a dermatologist are standard practice almost everywhere.
Skin cancer falls into two broad categories. Non-melanoma skin cancers — predominantly basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) — represent the vast majority of cases. BCC rarely spreads but can cause significant local tissue damage and scarring if neglected; SCC carries a real risk of metastasis if caught late and accounts for most non-melanoma skin cancer deaths. Melanoma is far less common but responsible for the majority of skin cancer fatalities overall. In Australia, one in 17 people will develop melanoma in their lifetime. In the US, more new cases of skin cancer are diagnosed each year than all other cancers combined — most of them BCCs and SCCs.
And yet, with rare exceptions, no country’s health authority recommends routine population-wide skin cancer screening for healthy adults. That apparent contradiction — common cancer, no screening programme — is worth understanding. The reasons behind it reveal something important about how screening works, and why individual risk matters far more than any blanket schedule.
What skin cancer screening involves
A professional skin cancer check — sometimes called a full-body skin exam — involves a clinician systematically examining all skin surfaces, including the scalp, between the fingers and toes, the soles of the feet, and the genitals. Dermatologists often use a dermatoscope, a handheld device with polarised light and magnification, which significantly improves the accuracy of assessing suspicious moles compared to the naked eye.
The ABCDE rule is the standard framework for assessing moles, both in clinical practice and for self-examination:
- A — Asymmetry: One half doesn’t match the other
- B — Border: Jagged, notched, or poorly defined edges
- C — Colour: Multiple shades or uneven colouring
- D — Diameter / Different: Traditionally defined as larger than 6mm (roughly the size of a pencil eraser), though modern dermatology increasingly emphasises “different” — a mole that looks or feels unlike your others — since many melanomas are caught at smaller sizes. The ugly duckling sign overlaps here: any lesion that stands out from the rest of your moles warrants attention even if it’s small.
- E — Evolving: Any change in size, shape, colour, or new symptoms like itching or bleeding
Who is at higher risk
Risk factors for melanoma and other skin cancers are well-established:
- Fair skin, light eyes, or red or blonde hair — Less melanin means less natural UV protection
- History of significant sunburn, especially blistering burns in childhood
- Many moles, or five or more atypical (irregular) moles
- Personal or family history of melanoma — roughly one in ten melanoma patients has an affected first-degree relative
- Outdoor work — agricultural workers, construction workers, and others with high cumulative UV exposure
- Immunosuppression — organ transplant recipients and others on long-term immunosuppressive medication face substantially higher risk
- Previous skin cancer — any prior melanoma, squamous cell carcinoma, or multiple basal cell carcinomas
Adults in any of these groups should be discussing a personalised checking schedule with a dermatologist or GP, irrespective of what general population guidance says.
What guidelines say by country
| Country / Region | Population screening? | High-risk recommendation | Authority |
|---|---|---|---|
| United States | No — insufficient evidence (USPSTF 2023) | Annual or more frequent dermatologist exam | USPSTF / AAD |
| United Kingdom | No national programme | GP or specialist referral for suspicious lesions | NHS / NICE |
| Canada | Not recommended for general population | Opportunistic assessment; annual for high-risk | CTFPHC |
| Australia | No national programme | Annual checks for high-risk; every 6–12 months for previous melanoma | Cancer Council Australia / RACGP |
| Germany | ✅ Every 2 years from age 35 (statutory) | Covered by standard programme | G-BA (Federal Joint Committee) |
Guidelines vary by country — check with your local health authority.
Why most countries don’t screen — and why Germany does
The core reason population screening hasn’t been adopted widely is that no randomised controlled trial has demonstrated that universal skin checks reduce melanoma mortality at a population level. That’s an unusually high bar, but it’s the same bar applied to other cancer screens.
The concern about screening harms is real. Skin cancer checks produce high rates of false positives — benign moles biopsied unnecessarily — and they can lead to overdiagnosis of indolent lesions that would never have caused problems. Every biopsy carries a small risk of complications, scarring, and anxiety. At population scale, those harms can add up even if individual risk is low.
Australia’s paradox is striking. The country has the world’s highest melanoma incidence and a deeply embedded sun-safe culture, yet Cancer Council Australia and the RACGP do not recommend routine population screening. Their position reflects the same evidence gap as other countries: public awareness campaigns, skin self-examination guidance, and targeted screening of high-risk groups are considered more proportionate than a national programme. This is contested by Australian dermatologists, many of whom recommend annual skin checks as standard practice. Notably, in 2025 the Australian Government allocated AU$10.3 million — led by the Melanoma Institute Australia and the AIHW — to develop a framework for a National Targeted Skin Cancer Screening Programme. Early data from this work confirms that any future programme would need to prioritise high-risk demographics: older males, people in regional and remote areas, and those in lower socioeconomic groups, who face disproportionately higher mortality. Targeted (risk-stratified) screening may be formalised in the coming years, even if universal population screening remains off the table.
Germany’s programme, introduced nationwide in 2008 after a successful pilot in Schleswig-Holstein, is the most significant outlier. Every adult 35 and over with statutory health insurance is eligible for a full-body skin exam every two years, conducted by a trained GP or dermatologist. Participation runs at around 47% of the eligible population. Longitudinal data from Germany’s Centre for Cancer Registry Data shows what critics feared: incidence spiked sharply after 2008 as the programme captured previously undetected cases, but population-wide melanoma mortality has remained largely flat across nearly two decades of screening. A clear reduction in deaths has not materialised. Germany continues the programme as part of routine preventive care, but its experience is now central to the global debate about whether population screening can ever achieve the mortality benefit that justifies its scale.
The US is divided internally. The USPSTF — which guides primary care clinicians — has issued an “I” statement (insufficient evidence) for skin cancer screening since 2016, reaffirmed in 2023. The American Academy of Dermatology, by contrast, recommends professional full-body skin exams and runs a national free screening programme. The two bodies are essentially measuring different things: whether to systematically screen everyone in primary care versus what specialist dermatologists should offer their patients. That gap creates real confusion for adults trying to work out what to do.
Self-examination and what it adds
Monthly skin self-examination is advocated by the AAD, the Skin Cancer Foundation, and Cancer Council Australia, even where professional screening isn’t universally recommended. The principle: regular self-examination helps people notice changes that can then be checked promptly by a clinician.
Self-examination has limitations — it’s harder to assess your own back, scalp, and other areas — but it remains the most accessible way to catch changes early, particularly between professional check-up appointments. Some people use a partner or trusted person to check hard-to-see areas.
Self-examination doesn’t replace professional assessment of a suspicious lesion. If you notice a mole changing, a new spot that looks different from your others, or anything that bleeds, itches, or won’t heal, see a GP or dermatologist — don’t wait for a scheduled annual check.
Fitting skin checks into a broader routine
Skin cancer checks sit differently from most other adult screenings discussed in the adults’ health screening guide — rather than a fixed population schedule, the frequency is driven almost entirely by individual risk. That risk-stratified model is increasingly common across preventive medicine: see also why over-screening causes harm for more on how guidelines weigh population-level benefits against individual harms.
One important overlap: dermatologists performing skin exams often provide opportunistic checks of areas reported as concerning. If you have a mole you’ve been meaning to get checked, booking a full skin exam — rather than a single spot check — means everything gets assessed in context.
Frequently Asked Questions
Keeping track of when your last skin check was — and flagging it when a year has passed — is easy to overlook. Screening Clearing is a free iOS and Android app for tracking your personal health screening schedule, including dermatologist checks alongside your other regular check-ups.
Start tracking your health checks today
Free for iOS and Android. Your data stays on your phone.
On your desktop or tablet?
Scan with your phone to open the app store directly — no searching needed.
Always consult your doctor for personal medical decisions.
Articles are written for educational purposes and reviewed against current NHS, CDC, and USPSTF guidelines. This content does not constitute medical advice. Always consult your doctor for personal medical decisions.
Sources
- USPSTF. Skin Cancer: Screening (2023). 2023.
- American Academy of Dermatology. Skin Cancer Screenings. 2024.
- Cancer Research UK. Screening for Skin Cancer. 2024.
- CTFPHC. Melanoma Guidelines. 2007.
- Cancer Council Australia. Melanoma — Detection and Screening. 2024.
- Australian Institute of Health and Welfare. Targeted Skin Cancer Screening — What Do We Know?. 2025.
- RACGP. Skin Cancer — Preventive Activities in General Practice. 2024.
- CDC. Skin Cancer Risk Factors. 2024.
Start tracking your health checks today
Free for iOS and Android. Your data stays on your phone.
On your desktop or tablet?
Scan with your phone to open the app store directly — no searching needed.
Always consult your doctor for personal medical decisions.